Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SCA-136 · 4 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| SCA-136 (200 mg) | DRUG | - |
| SCA-136 (400 mg) | DRUG | - |
| olanzapine (15 mg) | DRUG | - |
| placebo | DRUG | - |
| SCA-136 | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of schizophrenia * Ability to remain hospitalized for at least first 4 weeks of study * Needs hospitalization due to worsening of schizophrenia Exclusion Criteria: * Type 1 or 2 diabetes * Previous use of clozapine * Serious medical illness other than schi...
Top 15 of 16 competitors
SCA-136 is an investigational small molecule being developed by Pfizer, Inc. (ticker PFE) for the treatment of schizophrenia, a psychiatric disorder. It has been studied in Phase 1 and Phase 2 clinical trials, and it is also referred to as SCA-136 (200 mg).
SCA-136 is being evaluated as a treatment for schizophrenia, including acute exacerbations of the condition. It is an investigational therapy and has not been approved for commercial use. Clinical studies have enrolled both healthy volunteers and patients with schizophrenia.
Pfizer, Inc., which trades under the ticker PFE, is the developer of SCA-136. The company has sponsored four completed clinical trials of the drug, including Phase 1 studies in healthy Japanese and non-Japanese subjects and a Phase 2 study in patients with schizophrenia.
SCA-136 has completed Phase 2 clinical development. Four trials have been completed in total, three Phase 1 studies and one Phase 2 study, and no trials are currently active. The drug remains investigational and is not approved for marketing.
SCA-136 has been studied in four completed trials: NCT00505973 and NCT00447941 in healthy Japanese male subjects, NCT00458107 in healthy Japanese and non-Japanese female subjects, and NCT00265551, a Phase 2 study in subjects with acute exacerbations of schizophrenia. Total enrollment across these trials was 412 participants.